| Autor: |
Baird-Gunning, Jonathan J. D., Weerasinghe, Dinushi, Silsby, Matthew, Gawarikar, Yash, Carlino, Matteo S., Smith, Jessica L., Vucic, Steve |
| Zdroj: |
The Neurohospitalist; October 2018, Vol. 8 Issue: 4 p191-193, 3p |
| Abstrakt: |
Immunotherapy is a treatment strategy that has demonstrated survival benefit for metastatic melanoma. Ipilimumab and nivolumab are examples of immunotherapy, in which monoclonal antibodies antagonize cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 receptors, respectively, resulting in upregulation of the host immune response to cancer cells. There is increasing recognition of immune-mediated adverse events associated with immune therapies in patients with cancer. We present a case report of a patient who developed Miller Fisher syndrome associated with these therapies for metastatic melanoma along with a discussion of its management. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
